FOLR1 and ovarian cancer: By immunohistochemistry, strong FRα immunoreactivity was observed in ovarian cancers in contrast to moderate staining of FRα in borderline tumors and weak or absence of staining in benign cystadenomas/inclusion cysts (Figure 1C).